FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208082> ?p ?o ?g. }

• W4387208082 endingPage "S35" @default.
• W4387208082 startingPage "S34" @default.
• W4387208082 abstract "Decipher is a prognostic genomic classifier (GC) validated in several prospective NRG Oncology Phase III trials. Herein, we validate the GC in pre-treatment biopsy samples for risk stratification in a cohort of high-risk men treated with definitive radiotherapy and androgen suppression with or without docetaxel chemotherapy.As per a pre-specified and approved NCI analysis plan (Navigator #1061), we obtained available formalin-fixed paraffin-embedded tissue from biopsy specimens from the NRG biobank from patients enrolled on the NRG/RTOG 0521 randomized phase III trial. After central review, the highest-grade tumors were profiled on clinical-grade whole-transcriptome arrays (Veracyte, San Diego, CA) and GC scores were obtained. Pre-specified categorical GC scores, adjusted for archival tissue analysis, were used to define higher (>0.46) and lower (≤0.46) risk groups. The primary objective was to validate the independent prognostic ability of GC for metastasis-free survival (MFS) with Cox multivariable analyses (MVA).Samples were obtained from 283 consented, evaluable patients with tissue (50% of trial) yielding 183 (65%) GC scores that passed quality metrics, 91 from control and 92 from the interventional arm. Median age was 66 years, median PSA was 19.3 ng/uL (IQR: 8.1-41.4), 81% had clinical stage ≥T2 and 80% had Gleason score ≥8 (47% ≥9). Median GC score was 0.55 (IQR: 0.38-0.78) and overall the arms were balanced for key covariates. With a median follow-up of 9.9 years (IQR: 9.3, 10.7), 67 MFS events including 34 distant metastases (DM) were observed. On MVA, only the GC (per 0.1 unit) was independently associated with MFS (HR 1.12, 95% CI 1.01-1.25) as well as DM (sHR 1.22, 95% CI 1.06-1.41), whereas the 4 pre-defined trial risk groups used for stratification (based on Gleason score, T-stage and PSA), randomization and patient age were not. For categorical GC, on MVA, higher-risk GC patients (65%) had worse DM (sHR 2.82, 95% CI 1.1-7.3) compared to those with lower GC. Cumulative incidence of DM at 10-years was 27% for higher GC vs 9% (95% CI 7-18%) for lower GC. No biomarker-by-treatment interaction with GC and the addition of docetaxel was detected.In pre-treatment biopsy samples from a randomized Phase 3 trial cohort, GC demonstrated its ability to further risk stratify clinically high-risk men demonstrating an independent association of GC score with DM and MFS. High-risk prostate cancer is a heterogeneous disease state and GC can improve risk stratification to help personalize shared decision-making. NRG-GU009/PREDICT-RT (NCT04513717) aims to determine the optimal therapy based on GC score for high-risk prostate cancer." @default.
• W4387208082 created "2023-09-30" @default.
• W4387208082 creator A5000156180 @default.
• W4387208082 creator A5002909668 @default.
• W4387208082 creator A5006174923 @default.
• W4387208082 creator A5011710591 @default.
• W4387208082 creator A5013414580 @default.
• W4387208082 creator A5014582211 @default.
• W4387208082 creator A5015475982 @default.
• W4387208082 creator A5021685813 @default.
• W4387208082 creator A5023340968 @default.
• W4387208082 creator A5028611891 @default.
• W4387208082 creator A5036433314 @default.
• W4387208082 creator A5037247530 @default.
• W4387208082 creator A5042227397 @default.
• W4387208082 creator A5045162411 @default.
• W4387208082 creator A5063389942 @default.
• W4387208082 creator A5070623757 @default.
• W4387208082 creator A5073246821 @default.
• W4387208082 creator A5076238068 @default.
• W4387208082 creator A5078458765 @default.
• W4387208082 creator A5085318253 @default.
• W4387208082 date "2023-10-01" @default.
• W4387208082 modified "2023-10-17" @default.
• W4387208082 title "Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer" @default.
• W4387208082 doi "https://doi.org/10.1016/j.ijrobp.2023.06.300" @default.
• W4387208082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784480" @default.
• W4387208082 hasPublicationYear "2023" @default.
• W4387208082 type Work @default.
• W4387208082 citedByCount "0" @default.
• W4387208082 crossrefType "journal-article" @default.
• W4387208082 hasAuthorship W4387208082A5000156180 @default.
• W4387208082 hasAuthorship W4387208082A5002909668 @default.
• W4387208082 hasAuthorship W4387208082A5006174923 @default.
• W4387208082 hasAuthorship W4387208082A5011710591 @default.
• W4387208082 hasAuthorship W4387208082A5013414580 @default.
• W4387208082 hasAuthorship W4387208082A5014582211 @default.
• W4387208082 hasAuthorship W4387208082A5015475982 @default.
• W4387208082 hasAuthorship W4387208082A5021685813 @default.
• W4387208082 hasAuthorship W4387208082A5023340968 @default.
• W4387208082 hasAuthorship W4387208082A5028611891 @default.
• W4387208082 hasAuthorship W4387208082A5036433314 @default.
• W4387208082 hasAuthorship W4387208082A5037247530 @default.
• W4387208082 hasAuthorship W4387208082A5042227397 @default.
• W4387208082 hasAuthorship W4387208082A5045162411 @default.
• W4387208082 hasAuthorship W4387208082A5063389942 @default.
• W4387208082 hasAuthorship W4387208082A5070623757 @default.
• W4387208082 hasAuthorship W4387208082A5073246821 @default.
• W4387208082 hasAuthorship W4387208082A5076238068 @default.
• W4387208082 hasAuthorship W4387208082A5078458765 @default.
• W4387208082 hasAuthorship W4387208082A5085318253 @default.
• W4387208082 hasConcept C121608353 @default.
• W4387208082 hasConcept C126322002 @default.
• W4387208082 hasConcept C143998085 @default.
• W4387208082 hasConcept C2775934546 @default.
• W4387208082 hasConcept C2779466945 @default.
• W4387208082 hasConcept C2780192828 @default.
• W4387208082 hasConcept C2781190966 @default.
• W4387208082 hasConcept C509974204 @default.
• W4387208082 hasConcept C71924100 @default.
• W4387208082 hasConceptScore W4387208082C121608353 @default.
• W4387208082 hasConceptScore W4387208082C126322002 @default.
• W4387208082 hasConceptScore W4387208082C143998085 @default.
• W4387208082 hasConceptScore W4387208082C2775934546 @default.
• W4387208082 hasConceptScore W4387208082C2779466945 @default.
• W4387208082 hasConceptScore W4387208082C2780192828 @default.
• W4387208082 hasConceptScore W4387208082C2781190966 @default.
• W4387208082 hasConceptScore W4387208082C509974204 @default.
• W4387208082 hasConceptScore W4387208082C71924100 @default.
• W4387208082 hasIssue "2" @default.
• W4387208082 hasLocation W43872080821 @default.
• W4387208082 hasLocation W43872080822 @default.
• W4387208082 hasOpenAccess W4387208082 @default.
• W4387208082 hasPrimaryLocation W43872080821 @default.
• W4387208082 hasRelatedWork W1543388821 @default.
• W4387208082 hasRelatedWork W2010765098 @default.
• W4387208082 hasRelatedWork W2060708716 @default.
• W4387208082 hasRelatedWork W2094570582 @default.
• W4387208082 hasRelatedWork W2135620818 @default.
• W4387208082 hasRelatedWork W2407641156 @default.
• W4387208082 hasRelatedWork W2588988563 @default.
• W4387208082 hasRelatedWork W2735900144 @default.
• W4387208082 hasRelatedWork W2770702948 @default.
• W4387208082 hasRelatedWork W4246083279 @default.
• W4387208082 hasVolume "117" @default.
• W4387208082 isParatext "false" @default.
• W4387208082 isRetracted "false" @default.
• W4387208082 workType "article" @default.